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Monitoring the effect of gene silencing by RNAinterference in human CD34
cells injected into newborn RAG2/ c/ mice: functional inactivation
of p53 in developing T cells
Ramon Gimeno, Kees Weijer, Arie Voordouw, Christel H. Uittenbogaart, Nicolas Legrand, Nuno L.Alves,
Erwin Wijnands, Bianca Blom, and Hergen Spits
Tumor suppressor p53 plays an impor-
tant role in regulating cell cycle progres-
sion and apoptosis. Here we applied RNA
interference to study the role of p53 in
human hematopoietic development in
vivo. An siRNA construct speciﬁcally tar-
getingthehumantumor-suppressorgene
p53 was introduced into human CD34
progenitor cells by lentivirus-mediated
gene transfer, which resulted in more
than 95% knockdown of p53. We adapted
the human-SCID mouse model to opti-
mize the development of hematopoietic
cells, particularly of T cells. This was
achieved by the intraperitoneal injection
of CD34 precursor cells into newborn
Rag2/ c/ mice that lack T, B, and NK
cells. Robust development of T cells was
observed in these mice, with peripheral
T-cell repopulation 8 weeks after injection
of the precursor cells. Other lymphocyte
and myeloid subsets also developed in
these mice. Injecting p53 siRNA-trans-
duced CD34 cells resulted in stable ex-
pression and down-modulation of p53 in
the mature T-cell offspring. Inactivating
p53 did not affect the development of
CD34 cells into various mature leuko-
cyte subsets, including T cells, but it
conferred resistance to -irradiation and
other p53-dependent apoptotic stimuli to
the T cells. (Blood. 2004;104:3886-3893)
© 2004 by TheAmerican Society of Hematology
Introduction
The tumor suppressor p53 plays an important role in regulating the
cell cycle and apoptosis in response to DNA damage caused by
irradiation or exposure to genotoxic mediators. In addition, p53 can
mediate several cellular responses, including cell cycle arrest,
senescence, differentiation, and apoptosis, depending on the cell
type and the microenvironment.1 Although mutations occur in the
gene encoding p53 in human cancers, including tumors of hemato-
poieticorigin,itsfunctioninnormalhumanhematopoieticdevelop-
ment remains largely unexplored.
Recently, we obtained evidence that p53 plays a role in
regulating the replicative lifespan of mature human T cells in vitro
through the suppression of human telomerase reverse transcriptase
(hTERT) (R.G., E.W., R. Beijersbergen, and H.S., manuscript in
preparation). Telomeres are DNA repeats at the distal ends of the
chromosomes that protect against chromosome end-to-end fusion.2
Telomeres are shortened at each cell division, and cells with
critically short telomeres undergo cell cycle arrest and become
senescent.3-5 hTERT, which prevents telomere shortening, is tran-
siently up-regulated in T cells on stimulation through the T-cell
receptor(TCR),4,5andexpressionofadominant-negativemutantof
hTERT signiﬁcantly decreased the lifespan of CD4 and CD8 T
cells,5 indicating that hTERT plays a regulatory role in the lifespan
of human T cells. Recently, we observed that the down-regulation
of p53 by RNAinterference (RNAi) extends the lifespan of mature
human T cells and neutralizes the inhibition by dominant-negative
hTERT, indicating that p53 regulates hTERT expression in primary
human T cells. Given the function of p53 in mature human T cells,
we asked whether the p53 loss would affect the homeostatic
proliferation of T cells. Mice deﬁcient in p53 did not show obvious
defects in T-cell homeostasis. However, T cells from inbred mouse
strains have longer telomeres thanTcells from humans, resulting in
a delay in the onset of replicative senescence and in an extended
lifespan of these murine T cells. It is, therefore, of interest to test
the effect of p53 inactivation on human T-cell homeostasis.
In addition, we examined the role of p53 in thymic T-cell
development because studies in the mouse have revealed that p53 is
induced after the initiation of TCR rearrangement6 and that it plays
an important role in early T-cell development, speciﬁcally in
pre–T-cell receptor signaling.7 Results obtained in mice cannot
always be extrapolated to humans, and the role of p53 in human
T-cell development in the thymus is still unknown. To inactivate
p53 in developing T cells, we used RNA interference (RNAi),
which has emerged as a powerful method to silence target genes.
This method makes use of the property of short double-stranded
RNA to target mRNA for degradation.8 The recent demonstration
that stable expression of short-interfering RNA (siRNA) can be
achieved by retrovirus-mediated9 or lentivirus-mediated10 gene
transfer allows for silencing of genes in primary mammalian cells.
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knockout mice,11 to monitor the development of p53 siRNA-
transduced human stem cells into T cells and other lymphoid cells
in vivo. Using this model, we investigated the consequences of
knockdown of p53 on human hematopoietic development. We
injected p53 siRNA- and control-transduced CD34 cells intraperi-
toneally into newborn RAG2/ c/ mice and observed a robust
development of human mononuclear cells, including T cells in
animals injected with p53 siRNA- and control-transduced CD34
cells. In the mature T-cell progeny that developed from the p53
siRNA-transduced CD34 cells, p53 remained inactivated. We did
not observe obvious effects of p53 knockdown on the development
of human T cells or other hematopoietic cells in comparison with
untransduced or control-transduced CD34 cells. In contrast, we
noticed that the p53 siRNA-expressing T cells were more resistant
to p53-dependent apoptotic stimuli than untransduced or control-
transduced T cells. Besides giving speciﬁc information about the
possible role of p53 in T-cell development and homeostasis, these
experiments present a versatile, easy-to-manipulate model in which
the effects of gene knockdown on human hematopoietic develop-
ment in vivo can be examined.
Materials and methods
Mice
H-2d RAG2/ mice (kindly provided by Dr Antonius Rolink and Dr
Shunichi Takeda, Basel Institute for Immunology, Switzerland12) were
crossed with interleukin-2 receptor (IL-2R) c/ mice13 to obtain H-2d
RAG2/ IL-2Rc/ mice (further referred to as RAG2/ c/
mice).11,14 These mice are immunodeﬁcient because they show a total
absence of T, B, and NK lymphocytes.13 Mice were bred and maintained in
isolators and were fed autoclaved food and water. All manipulations were
performed under laminar ﬂow.
Fetal liver cell preparation
Human fetal liver was obtained from elective abortions. Gestational ages
ranged from 14 to 20 weeks. The use of this tissue was approved by the
medical ethical committees of our institutions and was contingent on
informed consent. Human fetal liver cells were isolated by gentle disruption
of the tissue, followed by density gradient centrifugation over Ficoll-
Hypaque (Lymphoprep; Nycomed Pharma, Oslo, Norway). Single-cell
suspensions were prepared by mincing tissues and pressing them through a
stainless steel mesh. Large aggregates were removed, and cells were
washed with medium before CD34 cells were isolated.
Transplantation of human CD34 cells into RAG2/ c/ mice
and evaluation of human cell engraftment
Enrichment of CD34 cells (more than 98% pure, as assessed by ﬂow
cytometry; data not shown) was performed using the CD34 Progenitor Cell
Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). CD34 cells
(0.2-2 million cells) were transplanted intraperitoneally into sublethally
irradiated (3.50 Gy) newborn RAG2/ c/ mice (younger than 1 week
of age). Peripheral blood (PB) was collected from the tail vein every 3 to 4
weeks after transplantation to determine the kinetics of human cell
engraftment. Mice were killed at different time points after transplantation,
and PB, liver, lung, spleen, bone marrow (BM), and thymus were evaluated
for the presence of human cells. Total body irradiation (TBI) was required
because nonirradiated mice do not show repopulation with human cells
(data not shown). Mononuclear cells were isolated by density gradient
centrifugation over Ficoll-Hypaque and were stained with anti–human
CD45 (Becton Dickinson, San Jose, CA) and other markers. Expression of
these markers was measured on a FACSCalibur (Becton Dickinson) and
analyzed with the FCS express program (Denovosoftware, Ontario, Can-
ada). The grafted human mononuclear population was deﬁned based on
forward and side scatter parameters, and the percentage of positive cells for
a given marker was determined for cells falling within the leukocyte and
CD45 gates. There were no cells present that reacted with the anti–human
CD45 in RAG2/ c/ mice that did not undergo transplantation.
Speciﬁc subsets of human cells were quantiﬁed by staining with anti–
human speciﬁc monoclonal antibodies (mAbs): CD11c, CD19, CD34, and
CD45RA(Coulter-Immunotech, Luminy, France); CD3, CD4, CD8, CD10,
CD14, CD16, CD20, CD56, CD83, and CD123 (Becton Dickinson); CD38
and CD45RO (DAKO, Glostrup, Denmark), and BDCA-2 (Miltenyi
Biotec), conjugated with different ﬂuorochromes.
Lentivirus production
Replication-defective self-inactivating HIV vectors were produced by
transient transfection of 293Tcells using FUGENE (Roche, Nutley, NJ) and
3 different plasmids. The plasmids used were the VSV-G envelope coding
plasmid pMD.G; the packaging plasmid pCMVDR8.91, designed to
provide the Gag, Pol, Tat, and Rev proteins to produce the virus particle;
and the transfer vector pTRIPU3-E1.15 pTRIPU3-E1 has been
modiﬁed to include the siRNAcassette from the pSUPER vector containing
the human p53 targeting sequence 5GACTCCAGTGGTAATCTAC, de-
scribed by Brummelkamp et al,9 and it carries the enhanced GFP gene
driven by the elongation factor-1 promoter. Twenty hours after transfec-
tion, medium was replaced byYssel medium,16 and 2 samples of virus were
collected at 24 and 48 hours. The virus-containing supernatants were
centrifuged for 10 minutes at 1800 rpm to remove cells and then were
passed through a 0.22-mm ﬁlter and kept at 80°C until use.
Transduction protocol
Transduction of CD34 human cells was performed by 1 cycle of overnight
exposure to viral supernatant on retronectin (Takara Shuzo, Otsu, Japan)–
coated 24-well plates in the absence of cytokines. The next day, cells were
washed and injected intraperitoneally into mice or kept in culture in Yssel
medium in the presence of thrombopoietin, stem cell factor, and IL-7 at 10
ng/mL each (all from Peprotech). The efﬁciency of transduction was
estimated by determining the percentage of green ﬂuorescence protein
(GFP)–positive cells, 2 to 3 days later, by ﬂow cytometry.
Western blot analysis
Total cellular extracts were prepared by lysing the cells in RIPA buffer for
30 minutes on ice. Equivalent amounts of proteins, determined by the
Bio-Rad Protein Assay (Bio-Rad, Munich, Germany), were loaded onto
10% sodium dodecyl sulfate (SDS) gels. p53 protein was detected using the
monoclonal antibody DO-1 (Santa Cruz Biotechnology, Santa Cruz, CA)
and -actin as a loading control using the polyclonal antibody I-19 (Santa
Cruz Biotechnology).
Human T-cell culture and analysis of the TCR repertoire
The expansion of human T cells from blood and spleen of RAG2/ c/
mice, reconstituted with human transduced stem cells, was performed by
stimulation with a feeder mix consisting of irradiated allogeneic human
peripheral blood leukocytes (PBLs) from 2 different donors and an
irradiated Epstein-Barr virus (EBV)–transformed B-cell line (JY), phytohe-
magglutinin (PHA; Gibco, Grand Island, NY), and recombinant human
IL-2 (rhIL-2; Roche, Nutley, NJ), as described.17 All the cultures involving
human cells were grown in Yssel medium. Analysis of the repertoire was
performed as described in Kostense et al.18
Detection of apoptotic cells
Cellular viability was analyzed by ﬂow cytometry, before or 24 hours after
gamma irradiation (30 Gy) or after treatment with staurosporine (1 M) or
ﬂudarabine (5 M). Cells were harvested and washed in ice-cold HEPES
(N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid) buffer (10 mM
HEPES, 150 mM KCl, 1 mM MgCl2, and 1.3 mM CaCl2, pH 7.4) and then
were incubated with allophycocyanin (APC)–labeled Annexin V (Becton
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cytometry, propidium iodide (PI; Sigma, St Louis, MO) was added (ﬁnal
concentration, 5 g/mL). Viable cells were deﬁned as negative forAnnexin
V and PI staining.
Results
Introduction of siRNA into human CD34 cells by
lentivirus-mediated gene transfer
Lentiviruses have 2 key advantages over other gene delivery
systems: they can infect noncycling cells, and they are not silenced
during development. Several groups have described the use of
small nuclear RNApromoters (H19 and U619) for the expression of
RNAi in mammalian cells. The H1 promoter was used to drive
expression of siRNA, designed to target the human p53 protein,
and lentiviral vectors expressing the siRNAcassette were prepared
(Figure 1A). A highly enriched population of CD34 cells was
isolated from human fetal liver and was subsequently transduced
with the siRNA/GFP-expressing lentiviral vectors. Transduction
efﬁciencies routinely ranged between 20% and 50%, as indicated
by the levels of GFP expression determined by ﬂow cytometry. No
obvious effect on cell growth or survival of the transduced cells
was observed in vitro after culture for 3 weeks in the presence of
cytokines, as described in “Materials and methods.”The proportion
of CD34-derived cells expressing GFP remained comparable to
that of the initial population (data not shown).
To demonstrate that the introduced construct was active and
able to knock down the expression of p53 in these cells, we sorted
the CD34 cells after transduction based on their GFP expression.
The expression of p53, which is usually low, is up-regulated
quickly after exposure of cells to several genotoxic stimuli,
including -irradiation. Untransduced and control-transduced (not
shown) cells responded to irradiation by increasing the levels of
p53, whereas the cells expressing the p53 siRNA construct did not
(Figure 1B), demonstrating that the construct was able to silence
gene expression in hematopoietic stem cells.
Effect of p53 knockdown on T-cell development
and homeostasis
To examine the effects of p53 knockdown on T-cell development,
we used the human-SCID mouse model pioneered by Dick and
colleagues.20 This model is based on the capacity of these primitive
cells (termed SCID-repopulating cells) to repopulate the BM of
C.B-17-Prkdcscid (SCID)21 mice and, more recently, NOD/LtSz-
Prkdcscid (NOD/SCID)22,23 mice with multilineage lymphoid and
myeloid cells. However, for the study of T-cell development, these
mice have limitations. T cell development was only occasionally
observed, apparently because of the presence of an active innate
immune system in the mice. Recently, we reported that CD34
cells—on intravenous injection into RAG2/ c/ mice, which
lackT, B, and NK cells—can develop into B cells and plasmacytoid
dendritic cells (pDCs).11 In addition, we observed that T cells
develop in these adult mice after intravenous injection of CD34
cells (results not shown). Although the success rate was 80%, it
took an average of 12 to 16 weeks to observe consistent T-cell
engraftment in the periphery. Moreover, the thymi of these mice
remained small (fewer than 0.8 	 106 human cells). Considering
thatthethymicmicroenvironmentofthe6-to8-week-oldRAG2/
c/ mice might not be optimal for humanT-cell development, we
decided to inject human precursors at an earlier time point.
Newborn (younger than 1 week), 1-week-old, and 2-week-old mice
were injected intraperitoneally with fetal liver–derived CD34
cells, and PB was analyzed 8 and 12 weeks after injection. Figure 2
shows that engraftment with human cells in the periphery is higher
in the youngest animals. Injection of 1-week-old mice also resulted
in signiﬁcant engraftment, but in 2-week-old mice human cells did
not develop after intraperitoneal injection of CD34 cells (Figure
2). Percentages of the CD3 population in the PB of 1-day-old
Figure 2. Intraperitoneally engraftment of newborn RAG2/ c/ mice at 1
day, 1 week, or 2 weeks of age, with CD34 fetal liver (FL) cells. Three groups
each of 4 newborn RAG2/ c/ mice—1 day (Œ), 1 week (E), or 2 weeks (	)o f
age—were intraperitoneally grafted with 0.5 	 106 MACS-selected CD34 FL cells.
At 4, 8, and 12 weeks after engraftment, all mice were bled, and the blood was
subjected to ﬂuorescence-activated cell sorter (FACS) analysis to determine the
percentage of CD45 human cells.
Figure 1. p53 knockdown in human hematopoietic precursors. (A) Schematic
representation of the lentiviral RNA interference vector pTRIPU3-EF1 p53. The
predicted short hairpin RNA targeting the human p53 is shown. (B) Human
hematopoietic progenitors (CD34) were isolated and transduced with the lentiviral
vector pTRIPU3-EF1 p53 and, after 1 week in culture with cytokines, were sorted
based on the expression of GFP. Cells were then -irradiated. Six hours later,
whole-cell extracts were prepared, separated using 10% SDS–polyacrylamide gel
electrophoresis (SDS-PAGE), and immunoblotted to detect human p53. The blot was
reprobed with an antibody against -actin as a loading control.
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(7.7% 
 4.7% and 4.3% 
 2.9%, respectively) and 12 weeks
(7.3% 
 2.4% and 7.1% 
 1.5%, respectively). The same was true
for the CD19 populations (87.2% 
 5.4% and 89.3% 
 3.7% at 8
weeks and 86.7% 
 4.5% and 78.3% 
 8.4% at 12 weeks). Thus,
the recovery ofTcells and B cells was increased in mice injected at
1 day of age compared with those injected at 1 week. In the
2-week-old mice, the percentages of CD45 cells were too low to
discriminate between CD3 and CD19 cells.
Analysis of 78 mice that were injected intraperitoneally be-
tween day 1 and 3 after birth revealed reconstitution with human
CD45 cells (Table 1) in 64 (83%) mice. Thirty-two mice showed
more than 50% reconstitution, and the rest showed between 10%
and 50% reconstitution.Any mouse with human CD45 cells in the
PB also had T cells in the thymus and other organs.
Thymic structure of mice injected intraperitoneally 1 day after
birth was examined by confocal microscopy 10 weeks after
transplantation. A differentiated thymus was observed with
CD1CD4 and CD4CD8 cells in the cortexlike region, and
single-positive CD4 and CD8 T cells were observed in the
medulla-like region (results not shown).
To further validate the newborn mouse model, we ﬁrst analyzed
the T cells in the thymus and various peripheral organs in a large
series of mice injected with untransduced CD34 fetal liver cells.
In addition we analyzed these mice for the presence of other
leukocyte subsets. Eight to 10 weeks after injection, 2 to 10 million
cells could be recovered from the thymus. Extensive ﬂow cytomet-
ric analysis (Figure 3) revealed the presence of all T-lineage
subsets, including double-positive CD4CD8 cells and single-
positive CD4 and CD8 T cells. Furthermore, a subset of the
CD3high cells expressed CD45RA. This population represents T
cells just before emigration to the periphery.24 Interestingly, CD25
was expressed on a subset of CD4 T cells that were likely
regulatory T (Treg) cells previously described by Stephens et al.25
The observation that these CD25CD4 cells are also highly
positive for glucocorticoid-induced tumor necrosis factor receptor
family–related gene (GITR) and cytoplasmic CTLA-4 (results not
shown) support the notion that these cells represent Treg cells. In
addition to TCR- cells and CD3CD56 T cells, the thymus
also contained substantial numbers of CD3CD56 NK cells, with
approximately half expressing CD16. The percentage of NK cells
(2%) was much higher than what is normally found in the thymi of
children (less than 0.1%). It is possible that the mouse thymus
environment favors the generation of NK cells. Alternatively, the
much higher proportion of NK cells may be a consequence of a
lower expansion rate of TCR- cells than occurs in a normal
human thymic microenvironment.We also observed relatively high
proportions of TCR- cells (1.5% vs less than 0.1% in a normal
thymus) and B cells (2.2% vs less than 0.1% in a normal thymus),
and these high percentages may be also a consequence of a low
expansion rate of TCR- cells. In contrast to the increased
percentagesofNK,B,andTCR-cells,thatofBDCA2CD123high
pDCs was within the normal range (0.1%).
The T cells that develop in the thymus migrate to multiple
anatomic locations. Variable percentages of T cells were found not
only in the thymus but also in BM, spleen, liver, and lungs (Figure
4). The BM had a low proportion (1%) of T cells, whereas in the
lung the percentage was 11%. The liver and spleen contained
comparable percentages of T cells. The CD4/CD8 ratios (3:1 to
4:1) were similar in all organs and were within the range normally
observed in humans. Interestingly, in the spleen and BM, a
population of CD3CD4CD25 cells could be detected that
presumably contained Treg cells and recently activated CD4 T
cells. Our results show that intraperitoneal injection of CD34 cells
into newborn mice results in a relatively rapid reconstitution of
human T cells in most mice.
As has been published by others using adult NOD/SCID mice26
and NOD/SCIDc/ mice,27 CD34 cells developed into multiple
lineages when injected into newborn RAG2/ c/ mice. B cells
were the most dominant cell population that developed in the PB
and in various organs in mice injected 1 day after birth. The highest
percentage of CD19 B cells was found in the BM (Figure 4A).
Not unexpectedly, most B cells in the spleen (Figure 4B) were
CD10CD20 cells and coexpressed immunoglobulin M (IgM)
and IgD. In the BM, most B cells were CD20CD10, suggesting
that the mouse BM is the site for human B-cell development.
Inspection of the BM (Figure 4A) revealed the presence of CD34
cells, a small percentage of which expressed only low levels of
CD38, suggesting that some primitive CD34CD38dim progenitor
cells remain in their undifferentiated state.
As described earlier,11 signiﬁcant numbers of pDCs were found
in all organs; pDCs were most clearly present in the BM (Figure
Table 1. Summary of results from 12 experiments
Human CD45 cells in PB, % No. mice (%)
Less than 10 13 (16)
10-30 16 (20)
30-50 17 (22)
More than 50 32 (42)
Seventy-eight newborn mice (younger than 1 week of age) were intraperitoneally
injected with 0.5 to 2.0 	 106 CD34 fetal liver cells. Mice were bled 6 to 11 weeks
after injection, and blood was analyzed using FACS. Percentages of CD45 cells in
the lymphocyte gate are given.
Figure 3. Repopulation of thymus of RAG2/ c/ mice, 11 weeks after
intraperitoneal injection with CD34 hematopoietic stem cells from fetal liver.
FACS proﬁles of thymi. Thymocytes were stained with antibodies against stem cell
markers CD34 and CD38,T-cell markersTCR  andTCR , CD1, CD3, CD4, CD8,
CD25, CD45RA, NK cell markers CD16 and CD56, plasmacytoid DC markers CD123
and BDCA2, and B-cell marker CD19. Cells in the analysis of CD16 and CD56 were
gated not only on CD45 cells but also on CD3 cells.
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4D). NK cells could also be detected in PB and various organs, but
in general the percentages were much lower than in the thymus.
CD11c and CD14 monocytes were observed in the organs
(Figure 4), indicating that not only human lymphoid but also
human myeloid development took place in these mice.
We then injected a series of mice with CD34 fetal liver cells
transduced with p53 siRNAor with an empty vector. Table 2 shows
that the percentages of thymocytes in GFP and GFP cells were
similar in mice injected with p53 siRNA and with control-
transduced CD34 cells. Similarly, we could not detect signiﬁcant
differences in the peripheries of these animals when liver or spleen
cells were analyzed. Thus, we conclude that inactivating p53 does
not lead to a survival advantage of p53 siRNA–expressing periph-
eral T cells.
Inspection of the thymi of mice injected with p53 siRNA and
control-transduced cells revealed the presence of GFP cells in the
CD4CD8 double-negative, double-positive, and single-positive
T-cell compartments. However, we did not observe differences in
the phenotypes of any of the subsets of T and non-T cells in the
thymus (Figure 5A) when gating on p53 siRNA GFP cells,
untransduced cells (GFP), or control GFP cells (not shown), nor
did we observe differences in the presence of T cells in any of the
p53 siRNAGFP or untransduced cells in the spleen.
Given the important role of p53 in the control of cell prolifera-
tion and the induction of apoptosis in response to DNAdamage, we
wanted to determine whether the reduced levels of p53 could have
an effect on the composition of theTCR repertoire.We investigated
TCR diversity in T cells isolated from mice injected with CD34
cellstransducedwiththep53iconstruct.Usingreversetranscription–
polymerase chain reaction (RT-PCR) analysis, we could establish
that all the V families were represented in the repertoire (Figure
5B). Furthermore, detailed analysis of the CDR3 region18 clearly
Figure 4. Repopulation of BM, spleen, liver, and lung of RAG2/ c/ mice 11 weeks after intraperitoneal injection with CD34 hematopoietic stem cells from fetal
liver. (A) FACS proﬁles of BM. BM cells were stained with antibodies against stem cell markers CD34 and CD38; T-cell markers CD3, CD4, CD25; NK cell markers CD16 and
CD56; plasmacytoid DC markers CD123 and BDCA2; B cell markers CD11, CD19, CD20; IgM and IgD; and myeloid cells markers CD11c and CD14. Cells in the analysis of
IgM and IgD are not only gated on CD45 cells but also on CD19 cells. (B) FACS proﬁles of spleen. Spleen cells were stained with the same antibodies as BM cells. (C) FACS
proﬁles of liver. Liver cells were stained with antibodies against stem cell markers CD34 and CD38, T cell marker CD3, plasmacytoid DC markers CD123 and CD4, and B cell
marker CD19. (D) FACS proﬁles of lung. Lung cells were stained with antibodies against T-cell marker CD3, plasmacytoid DC markers CD123 and CD4, and B-cell marker
CD19.
Table 2. T-cell development
Mouse Construct
CD45,
%
GFP in CD45,
%
CD3,%
GFP GFP
1 p53i 80.3 6.6 25.2 22.1
2 p53i 60.0 66.0 97.2 94.8
3 p53i 99.4 94.2 87.7 96.3
4 p53i 97.5 60.6 99.4 94.0
5 p53i 97.4 25.1 56.7 33.2
6 p53i 97.6 85.9 68.3 85.8
7 p53i 98.5 29.0 98.7 53.6
8 Control 45.2 5.2 25.9 32.4
9 Control 63.0 36.5 97.4 95.5
10 Control 99.0 99.0 95.7 76.0
Newborn mice were injected with CD34 fetal liver cells transduced with p53i
siRNA–GFP or control-GFP constructs. Mice were killed, and thymi were analyzed
using FACS. The percentages of CD3 cells in the GFP and GFP gates are given.
Percentages of CD45 cells and the proportion of GFP cells in this gate are also
indicated.
Figure 5. Multilineage presence of GFP-expressing cells in mice that under-
went transplantation with lentivirus-transduced human hematopoietic progeni-
tors. Newborn RAG2/ c/ mice were intraperitoneally injected with human
CD34 hematopoietic stem cells isolated from fetal liver and transduced with the
pTRIPU3-EF1 p53RNAi lentivirus. (A) Mononuclear cell suspensions from the
thymi and spleens of these mice were stained with various human-speciﬁc monoclo-
nal antibodies and analyzed by ﬂow cytometry. Cells positive for human CD45 were
gated and further analyzed, comparing the GFP and GFP populations. Examples
of T-cell development in thymi and spleens are given. Cells were stained with
antibodies directed to CD3, CD4, CD8, and CD56 and analyzed by FACS. (B) V
family representation from p53i GFP–expressing T cells in mice that underwent
transplantation with lentivirus-transduced human hematopoietic progenitors. RNA
was isolated from T cells, and the presence of different V subsets was determined
using RT-PCR.
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polyclonal (data not shown), indicating that the down-regulation of
p53 during T-cell development does not result in the prevalence of
some clones.
To interpret these results, it was important to verify the stable
expression and efﬁciency of the construct in knocking down the expres-
sion of p53 in cells isolated from the mouse periphery. Human mono-
nuclear cells, isolated from the spleens and blood of mice that underwent
transplantation 10 weeks earlier with transduced CD34 cells, were
cultured in the presence of human peripheral blood mononuclear cells
(PBMCs) from 2 donors, the EBV cell line JY, PHA, and IL-2. Under
these conditions, T cells proliferated extensively. Because only mature T
cells can be expanded using this protocol,28 our data indicate that the
human T cells that developed in the RAG2/ c/ mice were
functionally mature and could respond to signals triggered by TCR
ligation.Inaddition,theTcellswerecapableofrespondingtoalloantigens
and could produce a broad array of cytokines on restimulation in vitro,
indicatingthattheywereabletorecognizeandrespondtoforeignantigens
(data not shown). After expanding the T cells derived from the p53
siRNA–transducedCD34cellsinvivo,wesortedtheGFPandGFPT
cells and tested p53 levels after -irradiation from 2 mice subjected to
reconstitution. In both mice, p53 levels increased in the nontransduced
population, whereas p53 levels in cells containing the p53 siRNA
construct remained almost undetectable (Figure 6A). Consequently, these
p53 siRNA cells are less susceptible to apoptosis induced by -irradia-
tion or to treatment with ﬂudarabine (Figure 6B). In contrast, the loss of
p53 did not affect the sensitivity of T cells to apoptosis induced by
dexamethasoneandstaurosporine,whicharep53-independent,apoptosis-
inducing agents29 (Figure 6 and data not shown).
In addition to its proapoptotic function, p53 is also involved in the
induction of growth arrest in response to different stimuli. Moreover,
p53 is a negative regulator of hTERT, which regulates the replicative
lifespanofTcells.5Westudiedthegrowthofthep53siRNA–expressing
cells after TCR stimulation. The presence of GFP in our constructs
allowed us to examine the dynamics of a population of T cells
transduced either with p53i or with a control construct in relation to
untransduced cells. As can be seen in Figure 6C, we detected a
progressive accumulation of cells with reduced p53 content, indicating
that p53 siRNA T cells have a growth advantage compared with the
untransducedorcontrol-transducedcells.Interestingly,thesedifferences
were not detected shortly after stimulation but were detected only when
the cells were kept in culture for a longer time, indicating that the
immediate response to TCR stimulation is similar in p53 siRNA–
expressing cells and controls (Figure 6 and data not shown). These
resultsclearlyshowthatthep53siRNAintroducedintotheCD34cells
remained active in down-modulating p53 protein in the T-cell offspring.
Our data also indicate that although the down-modulation of p53
protects the T cells against some forms of stress and up-regulates
hTERT, it does not affect human T-cell development or homeostasis
in this system.
Lack of effect of p53 RNAi on development of B cells,
plasmacytoid DCs or monocytes in different organs
The fact that multiple lineages developed after the injection of
CD34 cells into newborn mice allowed us to analyze the effects of
p53 knockdown on the development of B cells, pDCs, and
monocytes. The percentages of B cells in the GFP and the GFP
populations are similar in cells developed from the control GFPand
thep53siRNAGFP–transducedCD34cells(Table3).Inaddition,
no differences in the expression of B-cell differentiation markers
were noted between untransduced control GFP and p53 siRNA
GFP cells (Figure 7). Moreover, we could also demonstrate that
knocking down p53 had no effect on the development of pDCs and
monocytes because the percentages of these cells in the GFP
populations were similar in untransduced, control-transduced, and
p53 siRNA–transduced samples (Figure 7).
Figure 6. Lentivirus construct is present and active in mature cells derived from
transduced human CD34 precursors. (A) T cells were isolated from spleens and
PB of mice reconstituted with transduced human CD34 cells and were expanded in
vitro and sorted based on the expression of GFP. Cells were then -irradiated. Six
hours later, whole-cell extracts were prepared, separated on 10% SDS-PAGE, and
immunoblotted to detect human p53. A Western blot with antibody against -actin
was used as a control. Results from 2 mice are shown. (B)Tcells expressing the p53i
or control-GFP constructs were treated with different stimuli and assayed 24 hours
later for apoptosis induction using a combination of propidium iodine (PI) andAnnexin
V double staining and ﬂow cytometry. Double-negative cells represent the viable
population (indicated by the percentages). (C) Reduced content of p53 favors the
outgrowth of mature T cells derived from human CD34 precursors. T cells were
isolated from spleens and PB of mice reconstituted with transduced human CD34
cells and were expanded in vitro, as described in “Materials and methods.” The
percentage of GFP cells was established by ﬂow cytometry at 2 different time points
after stimulation.
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We show here that the newborn RAG2/ c/ mouse provides a
useful model to study the effects of gene knockdown on the
development and function of human hematopoietic cells, particu-
larly of T cells. Robust T-cell development was observed with
intraperitoneal injections of CD34 cells into newborn mice and
proceeded at an accelerated pace compared with that observed
previously with adult mice (K.W., A.V., and H.S., unpublished
observations, September 2003, andYahata et al26, Hiramatsu et al27,
and Kerre et al30). A similar accelerated T-cell development was
observed after the injection of CD34CD38 cord blood cells
(results not shown). There are 2 possible explanations for the
acceleration of T-cell development in newborn mice: one is that the
thymic rudiment in adult mice is more atrophic than that of 1-day
old mice, perhaps as a result of thymic involution.31 The second
explanation is that 1-day-old mice have a less active innate immune
system. The idea that the murine innate system affects the human
T-cell population is based on the observation that preinjecting adult
RAG2/ c/ mice with lipid vesicles containing the drug
clodronate (which kills phagocytosing cells) strongly favors popu-
lating the mice with human peripheral T cells.32 In addition to
mainstream CD4 and CD8Tcells, all the other subsets ofTcells
could be observed, including TCR- cells, CD3CD56 T cells,
and CD25CD4 cells that could represent Treg cells.33 We also
observed the development of B cells, NK cells, pDCs, and
monocytes in the circulatory systems and peripheral organs of mice
injected with CD34 cells. In addition, CD15CD11cCD24
granulocytes and a low but consistent percentage of human
glycophorin–positive cells were present (data not shown).Together
these data indicate the generation of a complete repertoire of
human leukocytes in these mice, raising the possibility that these
newborn double-knockout mice can be used for studying “human”
immune responses in vivo. After we ﬁnished our current studies,
another group34 reported that some RAG2/ c/ mice injected
with CD34 neonatal cord blood cells at 1 day of age can develop
an adaptive immune response against tetanus toxoid antigen
and EBV.
By using siRNA directed against p53 in a lentiviral vector that
containedthemarkerGFPundercontrolofanindependentpromoter,we
demonstrated the feasibility of GFP to track the development of
genetically modiﬁed CD34 precursors in vivo. Biochemical analysis
revealed that in CD34 precursors, p53 siRNAexpression results in more
than 95% reduction in -irradiation–induced p53 expression. Given that
the siRNA construct remained stably and functionally expressed in the
T-cell progeny, we can safely assume that siRNA continues to be
expressed during the differentiation of CD34 cells into all mature
leukocytes. We did not observe signiﬁcant quantitative or qualitative
differences in leukocyte subsets that developed from p53 siRNA or
wild-type CD34 cells, indicating that the down-regulation of p53 does
not affect human hematopoietic differentiation. Our data are consistent
with those in p53-deﬁcient mice, which did not reveal a gross effect of
p53 deﬁciency on mouse hematopoietic development.35 It has been
reported that p53 in the mouse is up-regulated as a consequence ofTCR
gene rearrangements and that the down-regulation of p53 is required for
T-cell differentiation beyond the TCR- selection checkpoint.6,7,36 Our
data indicate that the premature down-modulation of p53 before the
TCR- selection checkpoint does not result in an advantage of
differentiation and proliferation of developing T cells. Recently, we
observed that p53 knockdown confers an in vitro expansion advantage
to human T cells (R.G., E.W., R. Beijersbergen, and H.S., manuscript in
preparation).Thiscanbeexplained,atleastinpart,bythefactthatp53is
a negative regulator of hTERT in T cells, which was previously shown
to determine the replicative lifespan of human T cells and, at the same
time, confers resistance to apoptotic stimuli.5 We therefore considered
the possibility that homeostatic expansion of T cells in vivo would be
promoted by p53 knockdown.This turned out not to be the case, though
p53 siRNA T cells isolated from mice showed the expected in vitro
growth advantage compared with control-transduced or untransduced T
cells. We observed that down-modulation of p53 renders the human T
cells resistant to -irradiation, consistent with the effect of p53 deﬁ-
ciency on resistance of mouse thymocytes to -irradiation.37,38 The
Figure 7. Multilineage presence of GFP-expressing cells in the BM and liver of
mice that underwent transplantation of lentivirus-transduced human hemato-
poietic progenitors. Newborn RAG2/ c/ mice were intraperitoneally injected
with human CD34 hematopoietic stem cells isolated from fetal liver and transduced
with the pTRIPU3-EF1 p53RNAi lentivirus. Mononuclear cell suspensions from
the livers and BM of these mice were stained with various human-speciﬁc monoclonal
antibodies and analyzed by ﬂow cytometry. Cells positive for human CD45 were
gated and further analyzed comparing the GFP and GFP populations Examples of
plasmacytoid DCs, myeloid cells, and B cells are shown. Liver and BM cells are
stained with antibodies directed to CD123, BDCA2, CD11c, CD14, CD10, CD34,
CD19, CD20, IgM, and IgD.
Table 3. B-cell development
Mouse Construct
CD45,
%
GFP in CD45,
%
CD19,%
GFP GFP
1 p53i 72.3 7.3 48.7 44.2
2 p53i 78.5 47.1 83.2 81.5
3 p53i 17.9 76.8 78.0 80.9
4 p53i 51.2 1.0 26.7 75.8
5 p53i 66.8 12.3 80.1 76.3
6 p53i nd nd nd nd
7 p53i 73.9 3.7 75.9 62.2
8 Control 68.5 8.2 27.7 44.8
9 Control 73.9 12.0 69.8 73.9
10 Control 10.0 73.1 63.6 67.6
Newborn mice were injected with CD34 fetal liver cells transduced with p53i
siRNA–GFP or control-GFP constructs. Mice were killed, and the BM was analyzed
using FACS. Percentages of CD19 cells in the GFP and GFP gates are given.
Percentages of CD45 cells and the proportion of GFP cells in this gate are also
indicated.
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lus, ﬂudarabine, conferred by the loss of p53 in human T cells, indicates
that p53 regulates the response to certain apoptotic stimuli, which may
make the T cells susceptible to transforming events. Indeed p53-
deﬁcient mice develop various neoplasms in 6 months. However, thus
far we have not observed hematopoietic tumors arising from p53
siRNA CD34 cells for as long as 6 months after injection of the p53
siRNA CD34 cells. This may be attributed to the fact that more
oncogenic hits and, thus, longer periods are required for the transforma-
tion of human p53-deﬁcient hematopoietic cells than for mouse
p53-deﬁcient hematopoietic cells.
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